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Background: The sublingual sufentanil tablet system (SSTS) is a novel hand-held patient-
controlled analgesia device developed for treatment of moderate-to-severe postoperative pain. 
Here we present the first results of its clinical use.
Methods: Adult patients undergoing major surgery in five hospitals in the Netherlands received 
the SSTS for postoperative pain relief as part of multimodal pain management that further 
included paracetamol and a nonsteroidal anti-inflammatory drug (NSAID). The following 
variables were collected: postoperative pain scores using the 11-point numerical rating score 
(NRS) at rest, number of tablets used, occurrence of nausea, and patient satisfaction scores.
Results: We included 280 patients in the study; the majority underwent laparoscopic abdominal 
(49%) or orthopedic (knee replacement) surgery (34%). The median NRS was 3.5 (interquartile 
range 2.3–4.0) on the day of surgery, 3.3 (2.3–4.0) on the first postoperative day, and 2.8 (2.0–4.0) 
on the second postoperative day; pain scores did not differ between surgery types. Mean number 
of tablets used was 19 (range 0–86). Nausea occurred in 34% of patients, more often in women 
(45% vs 19%). Overall satisfaction was high in 73% of patients. Satisfaction was correlated 
with pain relief (p<0.001) and inversely correlated with occurrence of nausea (p=0.01).
Discussion: In this data set obtained under real-life conditions we show that the SSTS effec-
tively managed postoperative pain in abdominal and orthopedic surgeries. Future studies should 
determine patient populations that benefit most from the SSTS, assess the added values versus 
intravenous patient-controlled analgesia, and determine the pharmacoeconomics of the system.
Keywords: acute pain, opioid, postoperative pain, sufentanil, sublingual formulation
Introduction
A recent development in the treatment of moderate-to-severe postoperative pain is 
the introduction of a sublingual sufentanil tablet system (SSTS).1–6 The SSTS system 
is developed by AcelRx Pharmaceuticals (Redwood City, CA, USA) and is marketed 
in Europe as Zalviso™ by Grünenthal GmbH (Aachen, Germany).5 The noninvasive 
hand-held SSTS is in fact a patient-controlled analgesia (PCA) device without the 
need for an intravenous (IV) catheter. The SSTS device holds a cartridge with 40 
microtablets, each of which contains 15 μg sufentanil. The patient operates the device 
by placing the tip, from which the tablet is released, under the tongue while activat-
ing the system through a unique thumb tag. After activation one tablet is released to 
the sublingual mucosa where it is slowly absorbed. The SSTS has a lockout period of 
20 minutes and the device can be used for up to 72 hours. In case of continuation of 
pain treatment beyond 72 hours, a new SSTS can be given to the patient or alternative 
analgesic regimens may be used.
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The SSTS has earlier been studied in a series of registra-
tion studies.1–3 Two randomized controlled trials compared the 
SSTS to placebo after orthopedic (knee or hip arthroplasty) 
or abdominal surgery. The SSTS provided better analgesia 
than placebo with somewhat greater efficacy in orthopedic 
than abdominal surgery.1,2 In a Phase III, randomized, open-
label study, the SSTS was compared to IV PCA morphine 
in abdominal and orthopedic (total knee or hip replacement) 
surgeries.3 Significantly more patients on the SSTS than IV 
PCA morphine rated their pain control as good or excellent 
(SSTS 78.5% vs IV PCA morphine 65.6%, p<0.01), using 
the patient global assessment of method of pain control. 
Additionally, the SSTS was not only noninferior to IV PCA 
morphine in terms of analgesia but also slightly superior.
In the Netherlands, the SSTS was introduced in August 
2016. Here we present the results of the first clinical 
experience (i.e., data obtained under real-life conditions) 
with the SSTS in patients following major predominantly 
laparoscopic-assisted abdominal procedures and orthopedic 
surgeries (predominantly total knee replacement surgery).
Methods
After a training phase in which both doctors and nurses were 
educated in its use, the SSTS was introduced in five hospitals 
in the Netherlands, two tertiary referral centers (Leiden Uni-
versity Medical Centre, Radboud University Medical Centre), 
and three secondary centers (Maasstad Hospital, Reinier de 
Graaf Hospital, and Alrijne Hospital), as an alternative to 
IV or oral opioid therapy in the treatment of postoperative 
moderate-to-severe pain. After the study was approved by 
the institutional review boards (identifier G16.075), the data 
were collected prospectively; the institutional review boards 
waived the requirement for written informed consent. Patient 
data confidentiality was maintained as all data were processed 
anonymously. Our initial focus was on tablet use, pain scores, 
prevalence of nausea, and patient satisfaction data. The SSTS 
was just one of the alternatives among a series of possible 
multimodal pain therapy options. The choice of the desired 
postoperative treatment (e.g., oral opioids, epidural analgesia, 
IV PCA with an opioid or the SSTS) is made during preop-
erative screening by the attending anesthesiologist together 
with the patient. We positioned the SSTS against standard 
postoperative analgesia care for major abdominal or orthope-
dic surgery, that is, oral opioids or IV PCA with morphine or 
piritramide, and all patients who previously would receive oral 
opioids or an IV PCA system were now given the choice of the 
SSTS. Exclusion criteria were 1) age <18 years; 2) inability to 
understand the instructions; 3) inability to operate the device; 
4) oral cavity surgery; 5) postoperative epidural analgesia; 6) 
known allergy to sufentanil. In one center, Maasstad Hospital, 
the SSTS was introduced as standard treatment for all patients 
after knee arthroplasty.
Most patients received general anesthesia with propofol 
induction followed by maintenance with either sevoflurane 
or propofol; most patients undergoing orthopedic procedures 
received spinal anesthesia. After surgery, all patients after 
general anesthesia were titrated to pain scores <4 (measured 
on an 11-point numerical rating scale ranging from 0, no 
pain, to 10, most severe pain imaginable) before the treat-
ment with the SSTS was started. Titration was according to 
local protocol and involved dose titration with morphine or 
piritramide. Patients after spinal anesthesia received the SSTS 
in the post-anesthesia care unit (PACU) and were instructed 
to use the system when they felt pain and (subjectively) felt 
the need for pain relief. Apart from the SSTS all patients 
received paracetamol and a non-steroidal anti-inflammatory 
drug (NSAID) three times per day as per local protocol. 
Antiemetic therapy (ondansetron, dehydrobenzoperidol, and 
dexamethasone) was given upon occurrence of nausea or was 
given preemptively in patients with known risk factors for nau-
sea (Apfel score). This was done according to local protocol.
The following data were collected: patient age, weight, 
and gender, type of surgery, tablet use (total number of 
tablets used and tablet use in the first 24 hours), duration of 
SSTS use, pain scores during SSTS treatment (mean daily 
numerical rating scores at rest [NRS-rest] derived from three 
measurements per 24 hours), concomitant pain medication 
apart from paracetamol or an NSAID, occurrence of nausea, 
and patient satisfaction score (scored once when the SSTS 
treatment was terminated, on a three-point qualitative scale: 
low, moderate, and high satisfaction). Data collection ended 
at the end of SSTS treatment. NRS values are presented as 
median ± interquartile range (IQR) to represent the general 
pain score during SSTS treatment. All other data are pre-
sented as mean (SD) or percentages.
Although this is an exploratory representation of a single 
treatment cohort we performed several pragmatic analyses. 
A multivariate analysis was performed to assess the influence 
of NRS, the presence of nausea, center, anesthesia type, and 
surgery type on patient-reported satisfaction scores. Gender 
effects on tablet consumption and NRS were analyzed using the 
Mann–Whitney test. As abdominal and orthopedic surgeries 
were most prevalent in our cohort with a substantial number 
of patients (186 and 95 patients for abdominal and orthopedic 
procedures, respectively), we compared the two groups with 
respect to NRS, tablets used, and satisfaction scores. The data 
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were analyzed using GraphPad Prism version 7 for MAC OS X, 
GraphPad Software, La Jolla, CA, USA, or SPSS (IBM Corp., 
IBM SPSS Statistics for Windows, version 22.0. Armonk, NY, 
USA). P-values <0.05 were considered significant.
Results
Three hundred patients were recruited in the study; we report 
on the data of 280 patients, as data acquisition was incomplete 
in 20 patients. Patient characteristics and study observa-
tions are summarized in Table 1. The majority of patients 
 underwent abdominal surgery (49%), of which 70% was 
performed laparoscopically (colon or rectum resection). The 
rest was either orthopedic (34%, knee replacement surgery) 
or other surgery (17%), including mastectomy, vascular sur-
gery, plastic surgery, thoracic surgery, or hernia correction.
The average number of consumed tablets was 18.6 (14.4) 
with a range of 0–86, corresponding to 279 (216) μg and 
range 0–1290 μg. The majority of tablets was consumed in 
the first 24 hours after surgery (13.3 [9.4], range 0–48; 199.5 
[141] μg, range 0–720 μg). Eight patients did not make use 
of the system, and 88 patients used fewer than 10 tablets. 
Eight patients used more than one cartridge of 40 tablets. 
The duration of the SSTS was on average 43.2 (21) hours, 
with one outlier, a patient who used the system for 160 hours. 
Most patients used the SSTS for 24, 48, or 72 hours. There 
was no difference in tablet consumption between men and 
women (19.7 [14.6] vs 18.4 [14.2] tablets; 295.5 [219] vs 
276 [213] μg). No correlation was found between weight 
and tablet consumption (p=0.75). On average, patients used 
0.48 (0.41) tablets per hour (7.2 [6.2] μg per hour) or one 
tablet (15 μg) every 2 hours. There was a small age effect 
with elderly patients using less tablets (reduced tablet use is 
0.2 tablet per hour, p=0.02).
As shown in Figure 1, median pain scores (IQR) on 
postoperative days 0, 1, and 2 during STTS treatment were 
3.5 (2.3–4.0), 3.2 (2.3–4.0), and 2.8 (2.0–4.0). Irrespective 
Table 1 Characteristics of Zalviso™ users and study observations
Variable Value
Number of patients included in the study 280
Men/women (n/n) 116/164
Age (years, median, range) 61 (18–86)
Weight (kg, mean ± SD, range) 83.9±18 (50–140)
Intra-abdominal surgery (n) 137
Orthopedic surgery (n) 95
Miscellaneous procedures (n) 48
Duration of Zalviso use (hours, mean ± SD, range) 43±21 (1–160)
Total tablets used (mean ± SD, range) 19±14 (0–86)
Tablets per hour (mean ± SD, range) 0.48±0.41 (0–2.0)
Tablets used in the first 24 hours (mean ± SD,  
range)
12±9 (0–48)
Tablets per hour in the first 24 hours (mean ± SD, 
range)
0.49±0.39 (0–2.1)
NRS-rest on the day of surgery (median, IQR) 3.5 (2.3–4.0)
NRS-rest on first day after surgery (median, IQR) 3.2 (2.3–4.0)
NRS-rest on second day after surgery (median, 
IQR)
2.8 (2.0–4.0)
Prevalence of nausea (total population) 34%
Nausea in men 19%
Nausea in women 45%
Satisfaction with pain treatment
Low satisfaction 12%
Moderate satisfaction 15%
High satisfaction 72%
Satisfaction in patients with an NRS >4
Low satisfaction 44%
Moderate satisfaction 19%
High satisfaction 36%
Satisfaction in patients without nausea
Low satisfaction 8%
Moderate satisfaction 14%
High satisfaction 78%
Satisfaction in patients with nausea
Low satisfaction 20%
Moderate satisfaction 21%
High satisfaction 58%
Satisfaction in patients with nausea and NRS >4
Low satisfaction 45%
Moderate satisfaction 22%
High satisfaction 33%
Notes: Zalviso™ manufacturered by Grunenthal GmbH (Aachen, Germany)
Abbreviations: IQR, interquartile range; NRS, numerical rating score.
Figure 1 Box plots of pain scores upon arrival in the post-anesthesia care unit 
(only the data from patients after general anesthesia were used), and pain scores of 
all patients observed during day 0 (day of surgery) and days 1 and 2 after surgery.
Note: Pain scores were obtained three times per day and the daily averages were 
used for analysis.
Abbreviation: PACU, post-anesthesia care unit; SSTS, sublingual sufentanil tablet 
system.
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of the treatment day 25% of patients reported an NRS-rest 
>4. NRS-rest was not correlated to patient weight. During the 
course of treatment, 28 patients (10%) had insufficient pain 
relief from the SSTS and required either rescue medication 
(e.g., IV methadone, IV esketamine, clonidine, tramadol, 
oxycodone) or were switched to IV PCA morphine, oral 
oxycodone, or subcutaneous morphine. Nausea occurred in 
34% of patients, 19% of men and 45% of women, pruritis 
occurred in five patients, sedation in four patients, delirium 
in four elderly patients, and respiratory depression in one 
patient (as detected by hypopnea and an increase in arterial 
partial pressure of carbon dioxide).
Twelve percent of patients reported low satisfaction, 15% 
moderate satisfaction, and 73% high satisfaction (Figure 2). 
Multivariate analysis indicated that satisfaction correlated to 
NRS at rest (p<0.001) and the presence of nausea (p=0.01). 
Neither satisfaction with pain relief nor the influence of pain 
or nausea on satisfaction with pain relief was related to gender, 
type of surgery, type of anesthesia, hospital, or age. Median 
NRS values at low, moderate, and high satisfaction were 4.1 
(2.8–5.2), 2.9 (2.3–4.0), and 2.7 (2.0–3.5), respectively.
Compared to orthopedic surgery, NRS-rest was slightly 
lower after abdominal surgery (2.8 [1.4] vs 3.2 [1.2], p=0.01). 
However, total tablet use was less in orthopedic patients 
(15.1 [11.0] vs 19.5 [14.4], p<0.01). There was no statisti-
cally significant differences in duration of SSTS use between 
abdominal and orthopedic surgeries (46±23 hours vs 41±15 
hours, p=0.10). Satisfaction scores were similar with high 
scores in 74% (abdominal patients) and 72% (orthopedic 
patients; Figure 2).
In Box 1 we report a collection of observed problems 
with the use of the system. Problems were diverse and were 
specifically related to tablets (e.g., problems with absorp-
tion), thumb tag, or the hand-held device (e.g., problems with 
operation). One patient shared one tablet with her roommate 
after she had activated the system herself.
Discussion
Our case series of 280 patients indicates that postoperative 
pain management with sublingual sufentanil is effective 
following a variety of surgical interventions. As part of a 
multimodal approach, sublingual sufentanil was effective in 
90% of patients. In 75% of patients pain scores were below 4. 
Satisfaction scores were high in 73% of patients, irrespective 
of gender or surgery type. Reduced satisfaction scores were 
related to the incidence of nausea and high pain scores. In 
10% of patients rescue medication was required or treatment 
was considered ineffective and changed to an alternative 
analgesic regimen. In our experience this is similar to other 
postoperative pain treatments such as IV PCA morphine or 
even epidural analgesia. The incidence of nausea in 34% of 
patients and the higher prevalence in women is not unex-
pected as sufentanil will evidently not be exempt of opioid-
related side effects. Earlier, we observed nausea in 52% of 
patients on IV PCA morphine, again with a higher occurrence 
Figure 2 Pie charts of satisfaction scores of patients treated with the sublingual sufentanil tablet system.
Notes: Panel (A) depicts all patients, panel (B) patients following abdominal surgery, and panel (C) patients following orthopedic surgery.
Orthopedic surgery
Low satisfaction
Moderate satisfaction
High satisfaction
Intra-abdominal surgeryAll patients
A B C
Box 1 Issues with the use of the sublingual sufentanil tablet system
Issues with the tablets
• Problems with tablet absorption because of dry mouth (n=4)
• Multiple tablets retained in the mouth because of dry mouth (n=1)
• Tablets found in bed (n=3)
Issues with the thumb tag
• The thumb tag had to be replaced (did not function/got off/got 
lost) (n=22)
• The thumb tag was swallowed (n=1)
• The thumb tag prevents smartphone use (n=1)
Issues with the hand-held device
• Difficulty with finding the mouth and/or lifting the tongue (n=2)
• Cap on device tip not removed by the patient (n=4)
• Device tethered to the bed got lost when patient switched beds 
(n=1)
• Device failure (no tablet released) (n=30)a
Miscellaneous issues
• Patient shares tablet with other patients (n=1)
Notes: aAll patients received a second system that was operational. This issue has 
been resolved by the manufacturer.
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in women than men.7 In the current study we did not collect 
data on antiemetic therapy. Furthermore, we did not take into 
account the use of opioids during anesthesia. Hence, future 
studies will have to ascertain whether sublingual sufentanil 
per se causes less nausea than other postoperative opioids. 
Additionally, it is important to realize that the choice for using 
the SSTS in this observational study was actively made by the 
anesthesiologist (together with the patient). This may have 
caused attribution bias. Still, the sample of patients presented 
in this report was very similar to those of our regular clinical 
practice. Furthermore, all patients in one center after knee 
arthroplasty were included.
The high satisfaction scores observed in the study of 
 Melson et al3 are in close agreement with our observa-
tion (78% vs 73%). These high satisfaction scores might 
be related to the relatively rapid onset of pain relief with 
sublingual sufentanil and the relatively low incidence of 
nausea. In contrast to the registration studies, we did not 
find a large difference in efficacy between orthopedic and 
abdominal procedures.
We found certain issues with the operation of the device 
(Box 1). For some, especially elderly patients, using the 
system was difficult and sometimes assistance was required. 
It is evident that the device is unsuitable for cognitively 
impaired patients (as is also true for IV PCA morphine), 
patients with a delirium, patients with coordination prob-
lems, patients who cannot hold the device in their hand 
(e.g., patients with severe rheumatoid arthritis), or patients 
after oral cavity surgery. In a few patients the dryness of the 
oral mucosa prevented sufficient absorption of the tablet. 
Most of the problems, however, are inherent to the intro-
duction of a relatively new technique with a learning curve 
for patients, doctors, and nurses. It is our experience that 
simply informing the patient how to operate the device is 
insufficient. In addition, several issues need to be considered 
(Box 1). Equally important, health professionals will need 
to determine the suitability of each patient for the SSTS. 
In our experience, the location and timing to assess suit-
ability are not limited to the preoperative screening clinic 
but suitability should be reassessed on the ward (or PACU) 
just prior to initiation of treatment. Evidently, postoperative 
patient conditions may be such that operation of the device 
is now more difficult than earlier anticipated.
The pharmacoeconomics of the system is an important 
issue. The current market price of the SSTS device in the 
Netherlands is €895 (US $1,100, BP £880) while the mar-
ket price of the consumables is €100 (US$125, BP £90) 
per patient, depending on the number of consumables pur-
chased (listing of February 2018). Not all patients included 
in our study were suitable for the SSTS treatment option. 
A substantial number of patients (31%) used <10 tablets 
during the course of the postoperative pain treatment, with 
15 patients using either no or just one tablet. Often this one 
tablet was a test tablet that was given to the patient by the 
nursing staff during the start of treatment. Patients who use 
only a few tablets are possibly better off with an alternative 
analgesic regimen, such as on-demand oral tramadol or 
low-dose oxycodone. Further experience with the system is 
needed to assess which patient population may benefit the 
most from the SSTS.
We observed no correlation between weight and tablet 
use or weight and NRS. This is an important observation and 
suggests that the fixed sufentanil dose serves a large variety 
of weights. The weight of our patients ranged from 50 to 140 
kg with 25% of patients with a weight above 90 kg and 25% 
with a weight below 70 kg. One has to be careful in using 
the SSTS in patients with weights below 50 kg as this may 
cause more intense opioid side effects. Similarly, pain relief 
from the SSTS in patients with weights above 140 kg may 
possibly be inadequate.
In conclusion, the sufentanil sublingual tablet system was 
without major complications in our cohort and is a viable 
alternative to IV PCA in postoperative patients without the 
need for an IV access. Future studies should 1) determine 
the patient populations that benefit most from the SSTS; 2) 
extend the comparison with IV PCA morphine in other surgi-
cal models; 3) compare the SSTS with other non-IV forms 
of analgesia, including epidural analgesia; and 4) perform an 
appropriate pharmacoeconomic evaluation of this new treat-
ment option. As item 4 is highly country-specific, separate 
analyses per country are needed.
Disclosure
Prof. Dahan received speaker/consultancy fees from AcelRx 
and Grünenthal. The authors report no other conflicts of 
interest in this work.
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